Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia
Status:
Not yet recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
Non-randomized, open-label, multicenter phase II Study for the treatment of
- 25 R/R BPDCN-IF (CD123/CD4/CD56 positive) AML patients and
- 25 patients presenting R/R AML CD123+, but negative for either, or both, CD4 and CD56.
Patients will be treated with 12 mcg/kg/day of tagraxofusp for 5 days, for at least 4 cicles.